Lexeo Therapeutics (NASDAQ:LXEO) Given New $9.00 Price Target at HC Wainwright

Lexeo Therapeutics (NASDAQ:LXEO) had its price objective trimmed by HC Wainwright from $15.00 to $9.00 in a report released on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other equities research analysts have also recently issued reports about the company. Chardan Capital decreased their price target on Lexeo Therapeutics from $22.00 to $20.00 and set a “buy” rating on the stock in a research report on Tuesday, May 13th. JPMorgan Chase & Co. decreased their price target on Lexeo Therapeutics from $16.00 to $10.00 and set an “overweight” rating on the stock in a research report on Friday, May 30th. Finally, Oppenheimer initiated coverage on Lexeo Therapeutics in a research report on Thursday, July 31st. They set an “outperform” rating and a $20.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $15.33.

Lexeo Therapeutics Price Performance

NASDAQ LXEO opened at $4.72 on Friday. The company has a market cap of $156.70 million, a PE ratio of -1.45 and a beta of 1.36. Lexeo Therapeutics has a 52 week low of $1.45 and a 52 week high of $12.76. The company has a quick ratio of 3.42, a current ratio of 3.42 and a debt-to-equity ratio of 0.01. The firm’s 50-day simple moving average is $4.32 and its two-hundred day simple moving average is $3.70.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.04. Research analysts predict that Lexeo Therapeutics will post -3.14 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Intech Investment Management LLC increased its position in shares of Lexeo Therapeutics by 20.7% in the second quarter. Intech Investment Management LLC now owns 13,682 shares of the company’s stock worth $55,000 after purchasing an additional 2,342 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Lexeo Therapeutics by 30.1% in the fourth quarter. JPMorgan Chase & Co. now owns 13,371 shares of the company’s stock worth $88,000 after purchasing an additional 3,093 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Lexeo Therapeutics by 49.9% in the fourth quarter. Wells Fargo & Company MN now owns 11,156 shares of the company’s stock worth $73,000 after purchasing an additional 3,714 shares during the last quarter. Bank of America Corp DE grew its position in Lexeo Therapeutics by 22.4% during the second quarter. Bank of America Corp DE now owns 26,653 shares of the company’s stock valued at $107,000 after acquiring an additional 4,883 shares during the last quarter. Finally, Barclays PLC grew its position in Lexeo Therapeutics by 9.9% during the fourth quarter. Barclays PLC now owns 55,161 shares of the company’s stock valued at $363,000 after acquiring an additional 4,951 shares during the last quarter. 60.67% of the stock is currently owned by institutional investors.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.